The exciting potential of this re-bridging technology is also supported by the work of Li et al. who employed a similar strategy to construct an ADC composed of an in-house EGFR antibody and a MMAE payload, for therapy of KRAS wild-type PaCa xenografts.22 Here, we contribute further significant advances to the field through the demonstration of CTX-MMAE efficacy in KRAS mutant models that reflect the high frequency of these mutations in PaCa patients, together with the inclusion of a predictive modelling tool to guide the successful application of our ADC. The gene discussed is EGFR; the disease is permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.